These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 35345317

  • 1. Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy.
    Brown ZJ, Hewitt DB, Pawlik TM.
    Front Biosci (Landmark Ed); 2022 Mar 05; 27(3):85. PubMed ID: 35345317
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.
    European Association for the Study of the Liver.
    J Hepatol; 2023 Jul 05; 79(1):181-208. PubMed ID: 37084797
    [Abstract] [Full Text] [Related]

  • 5. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
    Bai Y, Tong W, Xie F, Zhu L, Wu H, Shi R, Wang L, Yang L, Liu Z, Miao F, Zhao Q, Zhang Y.
    Aging (Albany NY); 2021 Jul 08; 13(13):17592-17606. PubMed ID: 34237708
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments.
    Capuozzo M, Santorsola M, Ferrara F, Cinque C, Farace S, Patrone R, Granata V, Zovi A, Nasti G, Ottaiano A.
    Mol Cell Probes; 2024 Feb 08; 73():101951. PubMed ID: 38244704
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hepatobiliary tumours.
    Simcock R.
    Practitioner; 2001 Aug 08; 245(1625):668-74. PubMed ID: 11524939
    [No Abstract] [Full Text] [Related]

  • 13. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M.
    Clin Mol Hepatol; 2022 Jul 08; 28(3):396-407. PubMed ID: 35032970
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of the distinct immune microenvironments between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Jiang S, Lu H, Pan Y, Yang A, Aikemu A, Li H, Hao R, Huang Q, Qi X, Tao Z, Wu Y, Quan C, Zhou G, Lu Y.
    Cancer Lett; 2024 Apr 28; 588():216799. PubMed ID: 38479553
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
    Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N.
    J Hepatobiliary Pancreat Surg; 2006 Apr 28; 13(6):537-42. PubMed ID: 17139428
    [Abstract] [Full Text] [Related]

  • 19. Nomogram based on inflammatory indices for differentiating intrahepatic cholangiocarcinoma from hepatocellular carcinoma.
    Chen L, Zeng F, Yao L, Fang T, Liao M, Long J, Xiao L, Deng G.
    Cancer Med; 2020 Feb 28; 9(4):1451-1461. PubMed ID: 31903730
    [Abstract] [Full Text] [Related]

  • 20. Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.
    Likhitrattanapisal S, Tipanee J, Janvilisri T.
    Tumour Biol; 2016 Sep 28; 37(9):12755-12766. PubMed ID: 27448818
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.